Cytonics, an early-stage biopharmaceutical company developing therapies for osteoarthritis, announced that the last patient has completed their last visit in the Company's first-in-human clinical trial of CYT-108, a novel recombinant protein variant of an endogenous, broad-spectrum protease inhibitor, delivered twice (90 days apart) via intra-articular injection into arthritic knees.

"We are deeply grateful to the patients, physicians, and research staff who made this study possible," said Joey Bose, President and CEO of Cytonics. "Reaching the last patient visit in our first-in-human trial of CYT-108 is a major milestone—not only for our company, but for the broader osteoarthritis community. Their participation brings us one step closer to validating a therapy that, if successful, may finally address the root molecular cause of OA. With Phase 1 now complete, our team is focused on cleaning and locking the database, and preparing for submission of our IND to the FDA later this year."

"This is an exciting moment for Cytonics," added Dr. Gaetano Scuderi, Founder and Chief Medical Officer. "Over the past 30 years, the search for a disease-modifying OA therapy has been marked by failure. CYT-108 represents a novel approach—engineered for multi-targeted inhibition of the proteases responsible for cartilage degradation. We believe this dual specificity and broad-spectrum activity sets CYT-108 apart from historical attempts, and may offer a meaningful step forward in how osteoarthritis is treated. We look forward to sharing our findings as we progress toward Phase 2 clinical trials."